恩威医药
(301331)
| 流通市值：24.62亿 | | | 总市值：24.69亿 |
| 流通股本：1.03亿 | | | 总股本：1.03亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 565,324,690.15 | 374,578,793.61 | 175,328,944.36 | 900,771,087.12 |
| 营业总成本 | 545,811,310.69 | 363,426,013.64 | 163,762,300.69 | 842,272,742.13 |
| 其他经营收益 | | | | |
| 营业利润 | 24,485,654.23 | 15,347,209.25 | 14,090,150.86 | 62,359,043.7 |
| 利润总额 | 27,370,189 | 17,954,539.98 | 13,882,903.43 | 64,163,756.05 |
| 净利润 | 22,423,830.06 | 16,022,873.88 | 12,504,732.32 | 51,944,936.65 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | 0 |
| 综合收益总额 | 22,423,830.06 | 16,022,873.88 | 12,504,732.32 | 51,944,936.65 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 857,589,910.5 | 856,468,554.85 | 920,020,713.92 | 975,462,846.46 |
| 非流动资产: | | | | |
| 非流动资产合计 | 580,004,129.03 | 581,200,146.73 | 578,863,880.52 | 575,199,716.74 |
| 资产总计 | 1,437,594,039.53 | 1,437,668,701.58 | 1,498,884,594.44 | 1,550,662,563.2 |
| 流动负债: | | | | |
| 流动负债合计 | 196,995,036.04 | 203,439,252.01 | 390,258,378.95 | 454,989,723.03 |
| 非流动负债: | | | | |
| 非流动负债合计 | 211,426,019.99 | 212,359,240.99 | 22,413,539.69 | 22,866,715.43 |
| 负债合计 | 408,421,056.03 | 415,798,493 | 412,671,918.64 | 477,856,438.46 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,029,172,983.5 | 1,021,870,208.58 | 1,086,212,675.8 | 1,072,806,124.74 |
| 股东权益合计 | 1,029,172,983.5 | 1,021,870,208.58 | 1,086,212,675.8 | 1,072,806,124.74 |
| 负债和股东权益合计 | 1,437,594,039.53 | 1,437,668,701.58 | 1,498,884,594.44 | 1,550,662,563.2 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 630,620,625.8 | 426,764,779.2 | 180,047,207.88 | 830,274,501.92 |
| 经营活动现金流出小计 | 544,821,472.88 | 360,700,253.57 | 183,539,527.9 | 720,681,639.81 |
| 经营活动产生的现金流量净额 | 85,799,152.92 | 66,064,525.63 | -3,492,320.02 | 109,592,862.11 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,380,135,977.15 | 859,120,925.44 | 401,229,699.93 | 1,672,288,578.5 |
| 投资活动现金流出小计 | 1,394,933,132.21 | 815,645,761.21 | 422,926,404.29 | 1,751,116,936.08 |
| 投资活动产生的现金流量净额 | -14,797,155.06 | 43,475,164.23 | -21,696,704.36 | -78,828,357.58 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 200,000,000 | 200,000,000 | - | 10,774,174.77 |
| 筹资活动现金流出小计 | 292,799,894.15 | 292,059,474.65 | 36,388,140.57 | 32,463,084.27 |
| 筹资活动产生的现金流量净额 | -92,799,894.15 | -92,059,474.65 | -36,388,140.57 | -21,688,909.5 |
| 汇率变动对现金及现金等价物的影响 | -251.04 | -186.24 | -93.5 | -136.37 |
| 现金及现金等价物净增加额 | -21,798,147.33 | 17,480,028.97 | -61,577,258.45 | 9,075,458.66 |
| 期末现金及现金等价物余额 | 276,501,100.88 | 315,779,277.18 | 236,721,989.76 | 298,299,248.21 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 17,480,028.97 | - | 9,075,458.66 |